We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Onion Extract Inhibits Bone Resorption

By Biotechdaily staff writers
Posted on 21 Apr 2005
Researchers studying osteoporosis used a rat model to show that a compound isolated from white onions decreased bone loss by inhibiting osteoclast bone absorption activity.

Osteoclasts are multinucleated cells that degrade and reabsorb old bone. More...
They lie in small cavities called Howship's lacunae, formed from the digestion of the underlying bone. The sealing zone is the attachment of the osteoclast's plasmalemma to the underlying bone. The osteoclasts release hydrogen ions into the cavity, acidifying and dissolving the mineralized bone matrix.

In addition, several hydrolytic enzymes are released by lysosomes to digest the organic components of the matrix, such as collagenase and cathepsin K. Products of digestion, such as calcium and phosphate ions, are absorbed into small vesicles that move across the cell and are eventually released into the extracellular fluid. Several hormones, including parathyroid hormone (PTH) and interleukin 6 (IL-6) regulate osteoclast activity.

Investigators at the University of Bern (Switzerland; www.unibe.ch) extracted onion powder and fractionated the extract by column chromatography and medium-pressure liquid chromatography. A single active peak was obtained by semi-preparative high-performance liquid chromatography. This material was tested on isolated rat osteoclasts growing in tissue culture and was found to reduce bone resorption.


The investigators reported in the March 30, 2005, online edition of the Journal of Agricultural and Food Chemistry that analysis of the onion fraction by high-performance liquid chromatography-electrospray ionization-mass spectrometry, time-of-flight electrospray ionization mass spectrometry, and nuclear magnetic resonance spectroscopy showed the active single peak to be gamma-L-glutamyl-trans-S-1-propenyl-L-cysteine sulfoxide (GPCS). It is a peptide with a molecular mass of 306 Daltons that demonstrated dose-dependent inhibition of osteoclast resorption activity with the minimal effective dose being about 2 mM.




Related Links:
University of Bern

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.